Eli Lilly, Novo Nordisk, and Sanofi cut insulin prices by up to 78%
Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government.
Eli Lilly, swiftly followed by Novo Nordisk and Sanofi, have all cut their prices for some of their insulin products in the USA, after requests from President Joe Biden and Senator Bernie Sanders.
Sanofi has cut the price point for one product, Lantus, by 78%, simultaneously capping the individual cost (the cost not covered by insurance) at $35 per month for patients with commercial insurance. For their shorter-acting medicine, Apidra, they have cut the price by 70%. The price cuts are due to take effect from January 2024, adding to other price reductions for insulin products Sanofi made last year. In June 2022 Sanofi stated it would slash the price of some of its insulin products from $99 to $35 per month for uninsured residents in the USA.
This initial price capping from Sanofi was in anticipation of a ruling in the Insulin Act, championed by Senate Majority Leader Chuck Schumer, to cap all insulin products at $35, until this was blocked by the Republican senate cohort. Later in the year, when the Inflation Reduction Act from President Biden came to pass, the prices were eventually capped at $35, but only for senior citizens in the Medicare Part D scheme.
“We launched our unbranded biologic for Lantus at 60% less than the Lantus list price in June 2022,” Olivier Bogillot, Sanofi’s US General Medicines Chief, commented. “Despite this pioneering low-price approach, the health system was unable to take advantage of it due to its inherent structural challenges.”
Eli Lilly was the first to cut prices, with a statement earlier in the month expressing that it would decrease the cost of it’s most prescribed insulin products by 70% as well as expanding their Insulin Value Programme, which also limits the out of pocket cost of insulin to $35 per month.
Senator Sanders pressed home Lilly’s example, calling out Novo Nordisk and Sanofi to follow suit. Novonordisk responded by reducing the price of it’s Novolog insulin by 75% and Novolin and Levemir by 65%, starting in 2024.
“We are pleased to see others join our efforts to help patients as we now accelerate the transformation of the US insulin market,” Bogillot stated. “Our decision to cut the list price of our lead insulin needs to be coupled with a broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? -
News Open letter challenges EU Commission on medicine supply chain
In an open letter to the European Commission, Medicines for Europe calls for a new medicine security contract with their goal to improve access to medicine and ensure a secure supply chain to Europe. -
News The Biggest Drug Approvals of 2022
A carefully curated list of the most notable drug approvals of the past year, covering neurology, oncology, and COVID-19, as well as a look at the most promising drugs up for review in 2023.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance